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Host natural killer immunity is a key indicator of
permissiveness for donor cell engraftment in patients
with severe combined immunodeficiency*
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Waseem Qasim, MBBSb London and Newcastle upon Tyne, United KingdomBackground: Severe combined immunodeficiency (SCID) can
be cured by using allogeneic hematopoietic stem cell
transplantation, and the absence of host immunity often obviates
the need for preconditioning. Depending on the underlying
genetic defect and when blocks in differentiation occur during
lymphocyte ontogeny, infants with SCID have absent or greatly
reduced numbers of functional T cells. Natural killer (NK) cell
populations are usually absent in the SCID-X1 and Janus kinase
3 forms of SCID and greatly reduced in adenosine deaminase
deficiency SCID but often present in other forms of the disorder.
Objective: To determine if SCID phenotypes indicate host
permissiveness to donor cell engraftment.
Methods: Aretrospectivedataanalysis consideredwhetherhostNK
cells influenced donor T-cell engraftment, immune reconstitution,
and long-term outcomes in children who had undergone
nonconditioned allogeneic stem cell transplantation between 1990
and 2011 in the United Kingdom. Detailed analysis of T- and B-cell
immune reconstitution and donor chimerism was compared
between the NK1 (n5 24) and NK2 (n5 53) forms of SCID.
Results: Overall, 77 children underwent transplantation, with
survival of 90% in matched sibling donor/matched family donor
transplants compared with 60% when alternative donors were
used. Infants with NK2SCID were more likely to survive than
NK1 recipients (87% vs 62%, P < .01) and had high-level donor
T-cell chimerism with superior long-term recovery of CD4 T-cell
immunity. Notably, 33% of children with NK1SCID requiredFrom athe Immunology and Bone Marrow Transplant Units, Great Ormond Street
Hospital for Children, London; bCellular &Molecular Immunology, Institute of Child
Health, University College London; cthe Bone Marrow Transplant Unit, Great North
Children’s Hospital, Royal Victoria Infirmary, Newcastle upon Tyne; and dthe Institute
of Cellular Medicine, University of Newcastle, Newcastle upon Tyne.
*This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/3.0/).
W.Q. and H.G. are supported by GOSHCC trustees.
Disclosure of potential conflict of interest: A.Worth is employed by Great Ormond Street
Hospital in London and has received payment for lectures from PasTest Ltd, as well as
from King’s College London; has received payment for the development of
educational presentations from PasTest; and has received payment for travel and
other meeting-related expenses from Great Ormond Street Hospital. A. Jones has
received payment for providing lectures from CSL-Behring, as well as for travel and
other meeting-related expenses. The rest of the authors declare that they have no
relevant conflicts of interest.
Received for publication August 19, 2013; revised February 21, 2014; accepted for pub-
lication February 25, 2014.
Available online May 1, 2014.
Corresponding author: Waseem Qasim, MBBS, Institute of Child Health, 30 Guilford St,
London WC1N 1EH, United Kingdom. E-mail: W.Qasim@ucl.ac.uk.
0091-6749/$36.00
 2014 American Academy of Allergy, Asthma & Immunology
http://dx.doi.org/10.1016/j.jaci.2014.02.042
1660additional transplantation procedures compared with only 8%
of children with NK2SCID (P < .005).
Conclusions: NK2SCID disorders are highly permissive for
donor T-cell engraftment without preconditioning, whereas the
presence of NK cells is a strong indicator that preparative
conditioning is required for engraftment of T-cell precursors
capable of supporting robust T-cell reconstitution. (J Allergy
Clin Immunol 2014;133:1660-6.)
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Severe combined immunodeficiencies (SCIDs) are a heteroge-
neous group of genetic disorders with common clinical phenotypes
presenting in early infancy with serious or recurrent infections and
failure to thrive. For more than 40 years, allogeneic hematopoietic
stem cell transplantation (allo-SCT) has provided curative therapy
for these disorders.1 There has been longstanding debate and con-
troversy around how and when to best perform transplantations in
infants given a diagnosis of SCID.2 Conventionally, conditioning
comprising myeloablative or submyeloablative chemotherapy is
used in patients undergoing allo-SCT to both eradicate host cellular
immunity and empty the bonemarrow niche in readiness for donor
stem cell engraftment. In small infants conditioning might carry
notable morbidity and mortality, and thus it has been long argued
that in the absence of host cellular immunity, sufficient donor cell
engraftment can be achieved without ablative conditioning. Some
centers strongly advocate infusion of unmanipulated donor grafts,
arguing that in the HLAmatched family donor (MFD) setting, suf-
ficient T-cell engraftment can be achieved without preconditioning
and that this can sustain long-term immune recovery.3-5 In general,
although these patients might not have significant levels of
multilineage stem cell engraftment, adequate donor T-cell
engraftment in combination with successful seeding of T-cell
precursor niches sufficient to maintain thymopoiesis can support
long-lived immune recovery. Engraftment of B-cell or myeloid
precursors is usually low or absent, and although a number of
children will recover antibody production, many will require
immunoglobulin replacement therapy for life.2 In the absence of
an HLA identical donor, stringently T cell–depleted mismatched
hematopoietic stem cell grafts can also mediate sustained
thymopoiesis, although in the absence of mature donor T cells,
recovery is slow and takes many months.
Analyses of SCID cohorts undergoing transplantation in
Europe and North America4,6-9 have given rise to the concept of
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nonconditioned allo-SCT with MSD or MFD donors (49/77 infusions) was
90%, and that after matched unrelated grafts (MUD) and haploidentical
(Haplo) transplantations (28/77 infusions) was 62%.permissive and nonpermissive host environments, and the
presence of host natural killer (NK) immunity might be an
important determinant in considering which infants require
preconditioning. Aside from donor matching, there are 2
additional and interrelated aspects of host NK immunity that
might be critical in determining successful outcomes in these
infants. First, innate cellular immunity mediated by macrophages
and NK cells might be a barrier against donor cell engraftment.10
Data from animal studies suggest that NK cell immunity plays a
crucial role in the rejection of allogeneic cells, particularly in the
HLA-mismatched setting.11 Second, underlying genetic defects
largely determine when lymphoid differentiation arrests during
ontogeny, and this in turn directly influences whether niches for
T-cell and NK cell precursors are occupied. Thus SCID disorders
caused by defective common gamma chain (SCID-X1)12 and
Janus kinase 3 (JAK3) SCID13 have circulating B cells but no
T-cell or NK cell immunity (T2B1NK2), reflecting a defect
that impedes common T/NK precursor development.
In other SCID disorders in which T-cell developmental arrest
occurs at a later stage of differentiation, NK development is
unaffected, and presumably the common T/NK precursor niche is
occupied, which might result in competition during engraftment.
SCID caused by adenosine deaminase (ADA) deficiency usually
affects multiple lineages and is associated with NK deficiency
(although less profound), and NK cell numbers might recover if
children are detoxified with enzyme replacement therapy with
PEG-ADA ahead of allo-SCT.
Previous surveys of transplantation outcomes for SCID
considered the importance of the SCID phenotype based on the
presence or absence of B cells, and T2B1 hosts fared better than
T2B2 recipients.14 The importance of host NK cell immunitywas
widely suspected, but incomplete recipient characterization
precluded detailed analysis. Here we report the United Kingdom
experience of nonconditioned allo-SCT for SCID disorders and,
for the first time, confirm that the presence of host NK immunity
is a key indicator of whether the host SCID environment is likely
to be permissive for donor cell engraftment.METHODS
Patients’ characteristics
Between 1990 and 2011, 77 infants (52 male) with SCID underwent
allo-SCT without preconditioning at 2 United Kingdom pediatric centers
commissioned to undertake such procedures (see Table E1 in this article’s
Online Repository at www.jacionline.org). All were T-cell deficient, with
absent T cells or reduced T-cell numbers with absent or severely impaired
proliferation responses to the mitogen PHA.
Age at transplantationwas similar for the groups and ranged from 1week to
17months,with amedian age of 3months and amedian follow-upof 3070days
for the NK1 group and 3001 days for the NK2 group (range, 760-7300 days).All children received antimicrobial prophylaxis and immunoglobulin
replacement therapy from the time of diagnosis. SCID phenotypes were deter-
minedon the basis offlowcytometry forT cells (CD3),B cells (CD19), andNK
cells (CD16/CD56) and, where indicated, had definedmolecular defects on the
basis of abnormal or absent protein expression, metabolite analysis, or
genetic mutations. Patients were grouped for analysis based on the presence
(>1003 106/L) or absence (<1003 106/L) ofNK cells at the time of transplan-
tation. This threshold reflects the lower limit of normal for age range ofNKcell
numbers in healthy infants. Bone marrow or cord blood grafts were infused
(n 5 49) in the matched sibling donor (MSD) or fully HLA MFD setting.
Bonemarrow or cord blood was also infused from 11 HLA-matched unrelated
donors. Haploidentical grafts were enriched for stem cells by using CliniMacs
CD34 selection (n5 17). No prophylaxis against graft-versus-host diseasewas
given to 35 infants, and the remainder received cyclosporine alone or in
combination with mycophenolate mofetil, prednisolone, or both.
Event-free survival was defined as survival without resorting to second
procedures, and where indicated, second procedures were undertaken with
conditioning. Details are provided in Table E1, where second procedures are
highlighted in gray below data for the primary infusion.
Engraftment and chimerism
Whole blood, granulocyte, or mononuclear cells were subjected to
chimerism analysis in all subjects. Where indicated, lineage-specific chime-
rism was also determined for CD3 (T cells), CD15 (myeloid lineage), and
CD19 (B cells) after magnetic bead selection from peripheral blood by using
an AutoMACS Pro-Separator (Miltenyi Biotec, Bergisch Gladbach, Ger-
many). The PowerPlex 16 system (Promega, Southampton, United Kingdom)
was used to PCR amplify 16 short tandem repeat loci in these patient samples.
The PCR products were then analyzed by using an AB3130 Genetic Analyser
with Gene Mapper v4.0 software (Life Technologies, Carlsbad, Calif).
Statistical methods
Kaplan-Meier curves were used to analyze survival figures. The log-rank
(Mantel-Cox) and Gehan-Breslow-Wilcoxon tests were used to compare
survival between different groups. Logistic regression was performed with
SPSS software (SPSS, Chicago, Ill) to identify determinants of survival after
hematopoietic stem cell transplantation in different groups.RESULTS
Survival of infants with SCID after allo-SCT
Overall survival after nonconditioned allo-SCT procedures
was 81%, with 90% survival after MSD or MFD infusions (49/77
procedures, Fig 1). Matched unrelated grafts and haploidentical
transplantations (28/77 procedures) had less favorable outcomes,
with survival of 62% in both groups. For comparison, over the
same period, overall survival after conditioned allo-SCT for
SCID was 72% (n 5 148), although confounding differences in
donor type and graft sources prevented controlled analysis against
FIG 2. A, Primary NK deficiency was defined as less than 100 3 106/L, and NK cell counts were low in chil-
dren with T2B1 SCID (SCID-X1 and Jak3 deficiency) and ADA deficiency. SCID disorders with normal NK cell
numbers (mean, 5383 106/L) were heterogeneous and included both T2B1 SCID and T2B2 SCID disorders.
B, On the basis of the absence or presence of NK cells, overall survival after nonconditioned transplanta-
tions for NK2SCID was 87% compared with 62% for NK1SCID (P < .01). C, Event-free survival, which was
defined as survival without the need for a subsequent procedure, was 81% for patients with NK2SCID
compared with 42% in the NK1 group (P < .005). NK1ve, NK1; NK-ve, NK2.
FIG 3. CD3 T-cell recovery was superior for patients with NK2SCID, with
normalization of counts inmost children, in contrast to those with NK1SCID
disorders. NK1ve, NK1; NK-ve, NK2.
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procedures involved unrelated donor or mismatched donor grafts,
whereas the majority of nonconditioned procedures usedmatched
sibling or family donors.
In contrast to previously described analyses based on the
presence or absence of host B cells,14 we found that transplantation
survival for both patients with T2B1 and those with T2B2 SCID
were similar (see Fig E1 in this article’s Online Repository at
www.jacionline.org). We next considered whether the presence or
absence ofNKcells could provide an indication ofwhich SCIDdis-
orders are amenable to nonconditioned transplantation. Primary
NK cell deficiency was defined as less than 100 3 106/L, which
is less than the normal range for infants aged 0 to 6 months (Fig
2, A). This group of infants were all T2B1, with underlying muta-
tions of the common g-chain or JAK3, giving rise to arrested T-cell
and NK cell development. In our cohort NK numbers in
patients with ADA-SCID were reduced at presentation (mean,87 3 106/L), and thus data for patients with ADA-SCID were
pooled with the NK2SCID group for overall analyses (n 5 53),
although reconstitution data were also considered independently
given that a number of these patients received enzyme replacement
therapy ahead of transplantation, which might have supported
detoxification and partial lymphocyte recovery. Patients with
NK1SCID disorders (n5 24) had intact NK numbers at diagnosis
(mean, 550 3 106/L) and were genetically heterogeneous, with
defined (RAG1, n 5 7; Artemis, n 5 2; IL-7 receptor, n 5 4; and
RMRP, n5 1) and undefined underlying disorders (n5 10).
Survival after nonconditioned transplantations for NK2SCID
was 87% compared with 62% for NK1SCID (P < .01; Fig 2, B).
Further analysis of the NK1 group found that the 9 infants with
known defects of VDJ recombination (RAG1, RAG2, and
Artemis) had poorer survival (56%) compared with those with
the other 15 NK1 disorders in whom survival was 71%.
Importantly, the overall number of children who required addi-
tional procedures was 33% in the NK1SCID group compared
with only 8% of children with NK2SCID. This resulted in an
event-free survival of 81% for patients with NK2SCID compared
with 42% for patients with NK1SCID (P < .005; Fig 2, C). For
these second transplantations, conditioning was administered in
6 children. In terms of complications, there was no difference in
the incidence of graft-versus-host disease (grade II or greater) or
viral reactivations between the NK1 and NK2 groups (Table E1).T-cell reconstitution and donor chimerism after
nonconditioned allo-SCT
At the most recent follow-up (2-20 years after transplantation),
the majority of children with NK2SCID disorders had peripheral
FIG 4. A, CD4 T-cell count recovery for NK1SCID was poorer than for
NK2SCID or ADA-SCID. The source of the donor graft is highlighted. F,
MFD; H, haploidentical; S, MSD; U, matched unrelated donor. B, Naive
CD4 T-cell recovery provided an indication of thymopoiesis, and recovery
was greatest in patients with NK2SCID, intermediate in patients with
ADA-SCID, and low in patients with NK1SCID. NK1ve, NK1; NK-ve, NK2.
FIG 5. High levels of donor T-cell (CD3) engraftment were achieved in
patients with NK2SCID and ADA-SCID, but a number of children with
NK1SCID had mixed T-cell chimerism. NK1ve, NK1; NK-ve, NK2.
J ALLERGY CLIN IMMUNOL
VOLUME 133, NUMBER 6
HASSAN ET AL 1663bloodCD3T-cell counts within normal ranges for age. In contrast,
T-cell recovery after nonconditioned allo-SCT for NK1SCID
variants was suboptimal for 13 of 19 evaluable children.
Interestingly, subgroup analysis found that recovery in patients
with ADA-SCID was poorer than for those with NK2SCID,
although superior than that for patients with NK1SCID (Fig 3).
Analysis of CD4 T-cell counts uncovered a similar pattern of
cellular recovery for the 3 groups, with immune recovery for
different graft sources (MSD, MFD, matched unrelated donor,
and haploidentical), as highlighted in Fig 4, A.
Where data for naive CD4 T-cell recovery were available, we
found that 12 of 19 children with NK2SCID compared with 3 of
16 children with NK1SCID had normal proportions of naive CD4
T cells for age (P < .005). Within the NK2 group, children with
ADA-SCIDwere again found to have intermediate levels of naive
T-cell recovery (Fig 4, B). Additional evidence of thymic output
based on quantification of T-cell receptor excision circles
(TRECs) was available on 30 children and was consistent with
superior thymopoiesis in the NK2SCID group, with a median
of 37,521 TRECs per million T cells compared with 1,705
TRECs/million T cells in the NK1SCID group. There was no
difference in CD4 T-cell recovery for infants treated before or
after 3 months of age (see Fig E2 in this article’s Online
Repository at www.jacionline.org).Lineage-specific donor chimerism after
nonconditioned transplantation
Using lineage-specific chimerism analysis, we found high
levels of donor T-cell (CD3) engraftment in patients withNK2SCID (mean, 98% donor CD3) and ADA-SCID (mean,
97% donor CD3), but a number of children with NK1SCID
(7/13 evaluated) had mixed T-cell chimerism (mean, 78% donor
CD3; Fig 5 and see Table E1). One of these subjects with a donor
T-cell chimerism of 61%was unusual in having had pretransplan-
tation T-cell counts of greater than 1000 3 106/L, although with
an abnormal T-cell receptor repertoire and impaired PHA
response. As expected, in the absence of preconditioning,
B-cell (CD19, see Fig E3 in this article’s Online Repository at
www.jacionline.org) and myeloid (CD15) chimerism (see
Fig E4 in this article’s Online Repository at www.jacionline.
org) in peripheral blood was limited to a small number of children
across the groups. Replacement immunoglobulin therapy was
withdrawn in 21 of 24 children with ADA-SCID, reflecting intact
host B-cell development and function in the majority of these
children once detoxification was established. In the NK1SCID
group, 11 of 17 infants have continued to receive immunoglobulin
replacement therapy. In the T2B1NK2SCID cohort immuno-
globulin replacement therapy was successfully withdrawn in 12
of 22 children, including some children with nomeasurable donor
B-cell chimerism, and here, host-derived B-cell immunity
appears to have recovered once donor-derived reconstitution of
T-cell help was established.DISCUSSION
The first bone marrow transplantation for SCID was success-
fully performed without preconditioning by using whole, unma-
nipulated sibling donor marrow in 1968.1 Over the following 4
decades, there have been notable improvements in overall
survival and long-term outcomes for the majority of infants
undergoing allo-SCT for SCID, but there remains controversy
over when grafts should be infused without conditioning and
which procedures are best performed with conditioning. Overall,
we found that survival after nonconditioned procedures was
superior to that after conditioned grafts performed over the
same period of time, but in the absence of directly matched cohort
comparisons, little emphasis can be placed on this finding. Rather,
our detailed analysis of outcome data from the nonconditioned
group might help determine which SCID disorders are most
amenable to correction in this manner and which subgroups
would most likely benefit from preparative chemotherapy. Even
then, important caveats must be considered while drawing
conclusions, including the limited information available defining
pretransplantation comorbidities in the NK2 and NK1 groups. In
addition, we note the molecular heterogeneity in the NK1 group,
FIG 6. Phenotypic classifications of SCID are based on the presence or absence of T, B, and NK cells. The
genetic basis of SCID disorders can now be elucidated in the majority of infants, although historically,
transplantation has often proceeded before mutations could be identified. T2B1NK2 disorders arise after
blocks in T and NK cell development, and we speculate that in these infants vacant and receptive bone
marrow niches are receptive and permissive for engraftment of donor-derived precursors without
conditioning. The presence of circulating NK cells is strongly indicative that common T/NK niches are
occupied, and this might result in engraftment competition with donor precursors. Certain disorders with
a T2B1NK1 phenotype (eg, IL-7 receptor deficiency and CD3 signaling defects) might be more permissive
than T2B2NK1 disorders, perhaps reflecting an intermediate stage of T-cell (but not NK cell) developmental
arrest. Here transplantation without conditioning might well be successful, but in other NK1 conditions,
including defects of VDJ recombination, conditioning is likely to be required to clear niches and secure
precursor engraftment. In the case of ADA-SCID, accumulation of toxic metabolites compromises all
lymphoid lineages as shown, but detoxification after nonconditioned transplantation can be sufficient to
ensure engraftment of long-term multilineage progenitors. CIITA, Class II transactivator; CLP, common
lymphoid progenitor; DNA-PK, DNA protein kinases; DP-T, double positive T cells; IL7Ra, IL-7 receptor a;
RAG, recombination-activating gene; RFX5, regulatory factor X5; RFXANK, regulatory factor X ankyrin
repeat containing; RFXAP, regulatory factor X5 associated protein RMRP, mitochondrial RNA-processing
endoribonuclease; Stim1, stromal interaction molecule 1; TAP, transporter associated with antigen
processing; ZAP70, z chain–associated protein of 70 kDa.
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poorer survival compared with the rest of the cohort, emphasizing
the importance of genetic characterization for detailed outcome
comparisons.
The absence of host T-cell immunity in patients with SCID
disorders provide a unique environment, which is considered
permissive for donor cell engraftment. Here we have considered
the importance of host NK immunity as a barrier to donor
engraftment and as an indicator of vacant thymic and prethymic
niches receptive to donor cell engraftment. NK cells are capable
of graft rejection, particularly in the nongenoidentical setting.11
In the context of patients with SCID, host NK cells might not
only act as a barrier to transplantation by mediating graft
rejection, but also their presence might indicate that stem cell
or lymphocyte progenitor cell niches are occupied and
nonreceptive to donor engraftment.
Most SCID disorders arise because of defective receptor
rearrangement pathways, loss of cytokine receptor expression,or abnormal signaling pathways, which result in a block in T-cell
and NK cell development. These conditions are defined by absent
or functionally abnormal T cells, with variable loss of B cells and
NK cell immunity. In rare cases there might be circulating T cells,
which have ‘‘leaked,’’ but in general, these are usually poorly
functional with a limited T-cell receptor repertoire and exhibit
impaired mitogen responses. In most conditions, in the absence of
conditioning, thymic and prethymic bone marrow stem cell
niches remain occupied with host progenitors, and donor
engraftment is restricted to the peripheral T-cell compartment.
The absence of NK development in patients with SCID-X1 and
JAK3 deficiency reflects a block in common lymphoid progenitor
development affecting T and NK cells but not B cells. In these
conditions the niche for T/NK common precursors is presumed
vacant, and we speculate that prethymic niches, early thymic
niches, or both are therefore receptive for donor T-cell precursor
engraftment, allowing sustained donor derived thymopoiesis. In
contrast, T-cell arrest in the majority of NK1SCID disorders
J ALLERGY CLIN IMMUNOL
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committed T-cell differentiation when T-cell receptor or CD4/8
coreceptor signaling is required. Here, replete precursor niches
are not receptive to engraftment, and unless preconditioning
with chemotherapy is undertaken, there might be competition
with donor precursors. Therefore long-term immune reconstitu-
tion in this context is largely dependent on postthymic T-cell
recovery and is therefore poorer than in patients with NK2SCID
disorders. ADA-SCID can be considered separately as a systemic
metabolic disorder in which accumulation of toxic metabolites
compromises lymphocyte and common lymphoid precursor. In
this disorder donor T cells and prethymic stem cell progenitors
engraft and mediate detoxification, leading to thymopoiesis and
multilineage immune reconstitution.
The risks of immediate conditioning-related toxicity have to be
balanced against later consequences that might arise as a result of
slow or poor immune recovery after nonconditioned procedures.
Chemotherapy preconditioning has evolved over time, and
improvements include the availability of targeted dosing or the
use of less toxic, reduced-intensity conditioning regimens.15-17
Nonetheless, in young infants there is a notable morbidity
and mortality associated with conditioned procedures, and
overall transplant-related mortality after such procedures is
approximately 20% at our centers. In infants with established
comorbidities, there might be heightened concerns relating to
the tolerability of preparative regimens, and thus the alternative
approach without conditioning might be much more attractive.
Finally, in some families late effects, including infertility
associated with myeloablative regimens, are a major concern,
and the option of a nonconditioned infusion is often favored.
Earlier cohort analyses considered reconstitution and survival
outcomes for SCID disorders based on T2B2 and T2B1
phenotypes, the latter faring better after nonconditioned infusions
of either whole marrow in the genoidentical setting or
hematopoietic stem cells in the T cell–depleted mismatched
setting.14 Establishment of donor B-cell chimerism and recovery
of B-cell function sufficient to withdraw immunoglobulin therapy
has been reported to be variable and unpredictable in these
children.18 In our cohorts there was no significant difference in
survival between B1 and B2 SCID disorders.
The additional characterization of SCID phenotypes on the
basis of NK activity provides a biological explanation for
engraftment permissiveness, especially in the HLA-mismatched
setting. Our findings broadly confirm improved survival and
better T-cell recovery in patients with T2B1 SCID because many
of these disorders are caused by defects of the common cytokine
receptor gc or JAK3, which result in a T2B1NK2 phenotype. The
molecular basis of NK1SCID disorders (Fig 6) is heterogeneous,
and although not yet fully defined for a number of children
reported here, included defects of VDJ recombination and
radiation sensitivity disorders in which survival was poorer. The
latter are usually T2B2NK1 and might not always be suitable
for conventional conditioning regimens but can tolerate
reduced-intensity preparations, which are capable of securing
engraftment of bone marrow stem cells with multilineage
potential. NK immunity is also preserved in IL-7 receptor defects
(T2B1NK1); a number of these infants are reported to have
successfully undergone unconditioned procedures, and some
have recovered antibody production.
Overall, our findings suggest that NK2SCID disorders
(including ADA-SCID) are highly permissive and receptive toallo-SCT, and conditioning is not required to secure satisfactory
long-term T-cell immunity, particularly in the matched sibling/
family donor setting. Longer-term follow-up is required to fully
determine the quality and longevity of immune reconstitution,
especially where ongoing immunoglobulin replacement is
required. In patients with NK1SCID, a high proportion of infants
required second procedures, and long-term T-cell recovery is
generally less good. There is a strong argument that the host
environment is less permissive in the majority of patients with
NK1SCID disorders, and therefore preconditioning should be
offered as the most effective way of securing engraftment as
part of a first and single procedure. Of course, there might be
situations in sick infants in which conditioning might not be
tolerated, and a pragmatic approach could require immediate
graft infusion without chemotherapy in the expectation that a
second conditioned procedure might be required. Finally,
identification of the molecular basis of these disorders before
allo-SCT should allow further stratification within the groups
and will help determine the need and intensity of preparative
regimens (Fig 6).
We acknowledge the valuable contributions of nursing and laboratory staff
and ongoing support from the United Kingdom national commissioning group
for SCID.
Clinical implications: The detection of circulating NK cells in
infants with SCID provides an indication that allogeneic
transplantation should be performed with chemotherapy
preconditioning.REFERENCES
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